Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
Language English Country Switzerland Media print
Document type Journal Article, Practice Guideline
PubMed
31151678
DOI
10.1016/j.eururo.2019.05.022
PII: S0302-2838(19)30426-9
Knihovny.cz E-resources
- Keywords
- Cabozantinib, Guidelines, Immune checkpoint inhibitors, Ipilimumab, Metastatic, Nivolumab, Pazopanib, Renal cell carcinoma, Sunitinib,
- MeSH
- Axitinib administration & dosage MeSH
- Bevacizumab administration & dosage MeSH
- Antibodies, Monoclonal, Humanized administration & dosage MeSH
- Ipilimumab administration & dosage MeSH
- Carcinoma, Renal Cell drug therapy secondary MeSH
- Humans MeSH
- Kidney Neoplasms drug therapy pathology MeSH
- Nivolumab administration & dosage MeSH
- Antineoplastic Combined Chemotherapy Protocols adverse effects therapeutic use MeSH
- Sunitinib therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Practice Guideline MeSH
- Names of Substances
- atezolizumab MeSH Browser
- avelumab MeSH Browser
- Axitinib MeSH
- Bevacizumab MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Ipilimumab MeSH
- Nivolumab MeSH
- pembrolizumab MeSH Browser
- Sunitinib MeSH
Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. PATIENT SUMMARY: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.
Department of Cancer Medicine Gustave Roussy Université Paris Saclay Villejuif France
Department of Clinical Sciences Lund Lund University Skåne University Hospital Malmö Sweden
Department of Surgical and Perioperative Sciences Urology and Andrology Umeå University Umeå Sweden
Department of Urology and Urologic Oncology Hannover Medical School Hannover Germany
Department of Urology Cabueñes Hospital Gijón Spain
Department of Urology Chaim Sheba Medical Center Tel Hashomer Ramat Gan Israel
Department of Urology Coimbra University Hospital Coimbra Portugal
Department of Urology Elbe Kliniken Stade Stade Germany
Department of Urology Ludwig Maximilians University Munich Germany
Department of Urology Royal Free Hospital Pond Street London UK
Department of Urology Sunderby Hospital Sunderby Sweden
Department of Urology University Hospital Schleswig Holstein Lübeck Germany
Department of Urology University of Rennes Rennes France
Division of Urology Maggiore della Carità Hospital University of Eastern Piedmont Novara Italy
The Royal Free NHS Trust and Barts Cancer Institute Queen Mary University of London London UK
References provided by Crossref.org
